MRVI241220C2500
- 2.20
- 0.000.00%
Maravai LifeSciences Newsroom
Co-Founder & Executive Chairman of Maravai LifeSciences Holdings Carl Hull Buys 174% More Shares
Maravai LifeSciences Initiated at Peer Perform by Wolfe Research
Maravai LifeSciences Analyst Ratings
Wolfe Research Initiates Maravai LifeSciences(MRVI.US) With Hold Rating
Estimating The Fair Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Maravai LifeSciences | 10-Q: Q3 2024 Earnings Report
Maravai LifeSciences Announces November 2024 Investor Conference Schedule
Morgan Stanley Maintains Maravai LifeSciences(MRVI.US) With Hold Rating, Cuts Target Price to $7
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript Summary
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript
Hold Rating on Maravai Lifesciences: Revenue Miss, Guidance Cut, and Market Challenges Amid Potential Upside From Officinae Bio Acquisition
Maravai Lifesciences Price Target Lowered to $9 From $10 at Baird
Top Midday Decliners
UBS Adjusts Price Target on Maravai Lifesciences to $8 From $11, Maintains Neutral Rating
Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $12
BofA Securities Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $9
Maravai Lifesciences to Buy Officinae Bio's DNA, RNA Business
Wall Street Awaits Post-Election Catalysts, Driving Muted Premarket Action for US Equity Futures
Decoding 5 Analyst Evaluations For Maravai LifeSciences
This Celanese Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday